



DAILY PROGRAMME HIGHLIGHTS

7th IAS Conference on HIV Pathogenesis, Treatment and Prevention Kuala Lumpur, Malaysia – 30 June - 3 July 2013

Please visit the online [Programme-at-a-Glance](http://www.ias2013.org) (www.ias2013.org) for a full list of conference sessions and satellite meetings taking place at the Kuala Lumpur Convention Centre or offsite, as well as the full list of affiliated independent events, including pre-conference events.

Please confirm all details and times on the PAG.

Press Conferences: A complete schedule of all press conferences, including those hosted by conference organizers and third parties, will be available on the Media Centre page of the conference website and will be posted outside the press conference room in the Media Centre. Please check for daily updates, available at the Information Desk in the Media Centre.

Please note that all the sessions taking places in Session Rooms 1-4 will be recorded and available online through the PAG after 24/48 hours, depending on the session.

SUNDAY, 30 JUNE

12:30 - 14:30 SATELLITE SESSION (SUSA03)

WHO Global Update on HIV Treatment: Results, Impact and Opportunities

Organizers: WHO

Location: Session Room 3

This satellite symposium presents the main findings from the WHO Global HIV Treatment and Care Update 2013. WHO will present and analyze the progress in the global scale-up of HIV treatment and care, identify critical issues, and discuss the main challenges and opportunities for maximizing the benefits of treatment provision. Global and regional data detailing progress towards the Universal Access target will be presented, and implications of the new eligibility scenarios based on 2013 WHO ARV guidelines will be discussed.

14:45 - 16:45 SATELLITE SESSIONS

• Launch of 2013 WHO Consolidated ARV Guidelines – What's the Evidence?

Organizers: WHO (SUSA04)

Location: Session Room 3

Launch of the 2013 WHO Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. The Guidelines include recommendations along the continuum of HIV care, including recommendations on HIV testing and counseling, ART initiation and maintenance, patient monitoring, 2nd and 3rd line ART, management of co-infections and comorbidities and service delivery. The satellite will present the science behind new key recommendations, including the rationale for deciding on when to initiate ART in different populations and the preferred regimens to use.

•Beyond Option B+ (SUSA06)

Organizers: UNICEF & International AIDS Society – Industry Liaison Forum

Location: Mini Room 3

As progress continues in the global plan to eliminate new HIV infections in children by 2015, revised WHO guidelines recommending Option B+ for prevention of vertical transmission (PVT) will create new challenges. Although PVT is highly effective, there is a high rate of loss to follow up of mother-infant pairs, compromising quality and effectiveness. The session will describe Option B+ implementation: from pregnancy through breastfeeding, including paediatric diagnosis, care, treatment and retention. Panel discussions will provide the opportunity to discuss the challenges and opportunities of Option B+ and paediatric diagnosis and care, aiming to identify novel methods to improve the health of infants and children, as well as their mothers.

15:00 – 17:00 AFFILIATED INDEPENDENT EVENT

High Level Panel on Drug Policy and Public Health

Organizers: Global Commission on Drug Policy and the IAS

Location: Impiana KLCC Hotel

This panel will discuss evidence-based solutions towards drug policy in Malaysia, elsewhere in Asia and globally and will present and debate the perspectives of key Malaysian drug policy authorities. The session will also present and debate the evidence, principles and recommendations produced by the Global Commission on Drug Policy (GCDP) in its three reports to date.

17:00 – 19:00 SATELLITE SESSION (SUSA01)

What to Consider When Initiating ART in Patients with HIV-Associated Comorbidities

Organizers: AbbVie

Location: Session Room 3

This symposium will address the challenges faced by physicians in managing comorbidities in HIV. The speakers will look at co-infections that are linked to, or associated with, HIV infection (cryptococcal meningitis, tuberculosis, hepatitis B & C), and at long-term neurological complications that may result from HIV disease and its treatment (HAND). In all these examples, the speakers will focus on patient management, offering insights into the latest thinking in these areas of care.

18:00 – 18.45 OFFICIAL OPENING PRESS CONFERENCE

Location: Media Centre, Press Conference Room

This press conference will feature opening session speakers, giving journalists the opportunity to gain a summarized preview of opening remarks.

19:45 – 20:45 OPENING SESSION (SUPL01)

Location: Session Room 1

The opening begins with welcoming remarks by: IAS 2013 Conference International Chair Françoise Barré-Sinoussi, IAS President and Director of the Regulation of Retroviral Infections Divisions, Institut Pasteur, Paris, France; Conference Local Co-Chair Adeeba Kamarulzaman, Dean of Medicine, University of Malaya, Kuala Lumpur, Malaysia; a representative of the Government of Malaysia (TBC); Andrew Tan, PLHIV Community Representative, Malaysian AIDS Council, Malaysia; Keynote address Speaker: Steve Deeks, University of California, San Francisco, San Francisco, United State.

Entertainment preceding the opening session will include a Gamelan performance by the University of Malaya Cultural Centre.

MONDAY, 1 JULY

8:50 – 10:30 PLENARY SESSION (MOPL01)

Location: Session Room 1

Presentations in this session:

Mean Chhi Vun, Cambodia, *Achieving Universal Access and Moving towards*

Elimination of New HIV Infections in Cambodia

Linda -Gail-Bekker, South Africa, *Pediatrics: The Transition from Adolescence to Adulthood*

Aziza Ahmed, USA, *HIV, Law and Stigma*

Grant Presentation: Collaborative Initiative for Paediatric HIV Education and Research

(CIPHER) Grant Programme Award Presentation: Women, Girls and HIV

Investigator's Award

11:00 – 11.45 OFFICIAL PLENARY PRESS CONFERENCE

Location: Media Centre, Press Conference Room

An opportunity for journalists to hear from the Monday plenary speakers.

11:00 – 12:30 SYMPOSIA SESSION (MOSY01)

Treatment 2013 – Current Issues and Future Directions

Location: Session Room 2

The session will provide an update on recent developments in HIV treatment, including new scientific evidence, country responses and progress towards achieving global treatment targets. It will present the new WHO clinical recommendations for ARV use among adults, pregnant and breastfeeding women and children. The rationale for these recommendations will be discussed along with major research gaps and operational and programmatic implications for countries in implementing the recommendations. The session will also look into the future of HIV treatment, to consider priorities for optimizing ARV drugs, ART regimens and HIV diagnostics.

12:45 - 14:00 MEET THE EXPERTS SESSION (MOME01)

Managing Treatment Failure in Developed and Resource Limited Settings

Location: Session Room 3

Despite advances in the management of people living with HIV, and the remarkable improvements in morbidity and mortality, treatment failure still occurs. Identification and management of patients who have failed first-line therapy remains a challenge particularly in resource limited settings. This interactive session with HIV treatment experts from a developed country and a resource limited country setting will address the approach to evaluating and managing treatment failure in these two different settings.

13:00 – 14:00 SPECIAL SESSION (MOSS01)

Evidence-Based Drug Policies for an Effective HIV Response

Location: Session Room 4

Why should physicians, researchers, service users, advocates and policy makers focusing on HIV learn and act for evidence-based narcotic drug policies? This question and others will be discussed by leading physicians, global health advocates and human rights defenders from Asia, Australia, Europe, and Latin America in an interactive panel. Two of the Global Commissioners from the Global Commission on Drug Policy (GDPC) will take part in the session. This session is co-organized by the International AIDS Society, the Global Commission on Drug Policies and International Doctors for Healthier Drug Policies.

14:30 – 16:00 SYMPOSIA SESSION (MOSY03)

Social and Structural Determinants of the HIV Epidemic in Eastern Europe and Central Asia

Location: Session Room 3

Recognising the inadequacy of public health responses that focus solely on individual behaviour change to improve population health outcomes, the aim of this session is to examine the social and structural factors related to the HIV epidemic in Eastern Europe and Central Asia, two regions currently most affected by rising HIV infections driven by injecting drug use.

14:30 – 15:15 OFFICIAL PRESS CONFERENCE

Late Breakers Track B

Location: Media Centre, Press Conference Room

An opportunity to hear late breaker speakers from Track B

14:30 – 116:00 ORAL ABSTRACT SESSION TRACK C (MOAC02)

Treatment as Prevention: A Work in Progress

Location: Session Room 1

18:30 – 20:30 SATELLITE SESSION (MOSA03)

Closing the Treatment Gap for Children Living with HIV

Organizers: Medicines Patent Pool, UNITAID, and Drugs for Neglected Diseases initiative (DNDi)

Location: Mini Room 3

While antiretroviral treatment for children with HIV has come a long way, the treatment coverage in children at 28% still lags far behind that of adults coverage of 57%. This satellite aims to look at the bottlenecks in getting treatment to children, such as availability of point-of-care early infant diagnosis, availability of most efficacious and adapted paediatric formulations for use in resource poor settings, healthcare workers perception of challenges in treating children, intellectual property rights and trends in the paediatric markets. It will also look at what is required for closing the treatment gap.

08:55 - 10:30 PLENARY SESSION (TUPL01)

Location: Session Room 1

Presentations in this session:

Daniel Douek, USA, *The Relationship between HIV Disease and Inflammation*

Javier Lama, Peru, *State of the Evidence from Oral and Topical PrEP Efficacy Trials: What We Know and What We Still Need to Know*

Barbara de Zalduondo, Switzerland, *Social Determinants: Structural Barriers*

Award Presentation: The 2013 IAS/NIDA Fellowship Programme Award will be given at the start of this session.

11:00 – 11:45 OFFICIAL PLENARY PRESS CONFERENCE

Location: Media Centre, Press Conference Room

An opportunity for media to hear from the Tuesday plenary speakers.

11:00 – 12:30 SYMPOSIA SESSION TRACK D (TUSY02)

Financial and Non-Financial Incentives for HIV Prevention and More Effective Treatment Outcomes: How, Where and When Do They Work?

Location: Session Room 4

The session will focus on the use of financial and non-financial incentives to achieve behaviour change among individuals and providers and to improve programme outcomes – with the ultimate goal of preventing new HIV infections and increasing the effectiveness of HIV treatment. The session will also describe ways in which incentives have been and could be used, when to consider lottery-based rewards as opposed to other forms of compensation and rewards, how such programmes are funded, and what might happen when the programmes are over.

11:00-12:30 ORAL ABSTRACT SESSION TRACK B (TUAB01)

Viral Hepatitis and HIV CO-Infection: lessons from the Real World

Location: Session Rom 1

12:00 – 12:45 PRESS CONFERENCE

Late Breakers Track A

Location: Media Centre, Press Conference Room

An opportunity to hear late breaker speakers from Track A

12:30 – 14.00 SPECIAL SESSION (TUSS02)

IAS Members' Meeting: 'None Left Behind' – the IAS's Work with Key Affected Populations

Location: Session Room 4

This session will feature an update on the progress of the IAS's strategic priorities for 2013 and 2014. There will also be presentations related to the IAS's work with key affected populations, followed by a discussion. Participants will have an opportunity

to network with speakers and members at a reception after the session. The format will be informal and interactive.

13.00-14.00 SPECIAL SESSION (TUSS01)

Mobile Versus Clinic-Based HIV Teasting: Results of the Project Accept RCT

Location: Session Room 2

Project Accept (HPTN 043) was a large community randomized trial of standard clinic-based HIV voluntary counselling and testing (VCT) versus mobile VCT, community engagement, and post-test support services. The study found markedly higher rates of testing uptake, particularly among men. This session will describe the study and review the outcomes, and suggest the implications of the Project Accept study for HIV programmes and for future HIV prevention and treatment research at community levels.

14:25-16:00 SYMPOSIA SESSION (TUSY03)

Symposia Session: Population-Based Tuberculosis Control: What Will it Take to Bring about Control Globally?

Location: Session Room 2

In the last 120 years, population-based TB control has been achieved in certain regions, cities, and settings around the world. Despite TB treatment and vaccines, diagnostics and a better understanding of the organism, we still fail to control TB in many parts of the world. It is thought that the 4 I's - Isonicotinylhydrazine (INH) prophylaxis, Infections control, Intensified case finding and Integration of TB and HIV services - together with the World Health Organization's recommended tuberculosis control strategy - Directly Observed Therapy Shortcourse (DOTS) - will be sufficient to do this. This symposium will examine these prospects in greater detail.

14:30 – 16:00 BRIDGING SESSION ((TUBS02)

HCV - Is Your Patient Being Left Behind? New Options and Unmet Needs

Location: Session Room 1

This session will review and address many of these issues, including prevention of HCV in those living with HIV, and difficulties in identifying and treating those with co-infection. A panel of experts will also offer some guidance on appropriate care models and will review therapy options for those with non-genotype 1 infection, non-responders, and relapsers, including a discussion of interferon-free strategies. Finally, the session will offer some strategies regarding management of HIV/HCV co-infection in resource-limited settings.

14:30 – 16:00 SYMPOSIA SESSION (TUSY04)

New Approaches to Assess the Population Level Impact of New Prevention Technologies

Location: Session Room 3

An efficacy trial (HPTN 052), as well as ecological and cohort studies, have found that earlier initiation of ART can decrease HIV transmission, while several studies have demonstrated that other biomedical interventions, such as adult male circumcision, can decrease incidence. Many questions, however, remain as to whether these interventions can be brought to sufficient scale to stop the epidemic.

Additional concerns include the potential for risk compensation and the challenges to infrastructure as these interventions are expanded on a large scale. This symposium will highlight and review new research methodologies that are being developed to enable researchers, clinicians and public health officials to evaluate the intended and unintended consequences of the expansion of HAART, other biomedical interventions, as well as behavioral approaches to slowing the spread of HIV.

14:30 – 15:15 OFFICIAL PRESS CONFERENCE

Towards an HIV Cure

Location: Media Centre, Press Conference Room

An opportunity to hear speakers talk about the late breakers on HIV Cure related research

16:30-18:00 ORAL ABSTRACT SESSION TRACK D (TUAD01)

Two Sides of the Same Coin: Demand Creation and Supply Strategies for HIV Services

Location: Session Room 1

16:30 – 18:00 SYMPOSIA SESSION (TUSY05)

Symposia Session: HIV Vaccines and Future Strategies

Location: Session Room 3

Five candidate vaccines have been tested in large scale clinical trials, and only one (RV144, tested in Thailand) resulted in a moderate level of protective efficacy (31.2%). The most recent trial, HVTN 505, a prime-boost combination, was stopped for lack of efficacy. This session will review past HIV vaccine efforts, as well as novel viral vectors and advances in the design of vaccines to induce neutralizing antibodies. A panel will discuss options to accelerate the development of a much needed HIV vaccine.

18:30 – 20:30 SATELLITE SESSIONS

Towards “Zero Discrimination”: What Can Scientists Do to Help End HIV-Related Restrictions on Entry, Stay and Residence? (TUSA02)

Organisers: IAS, UNAIDS, EATG and GNP+

Location: Mini Room 2

This satellite session will assess progress and challenges in efforts to review and eliminate HIV-related entry, stay and residence restrictions, with a particular focus on the role the scientific community can play in promoting evidence-informed and human rights-based migration policy.

3rd Annual Decade of Diagnostics Satellite- 2013 Update Strategic Deployment of CD4 and Viral Load Testing: How Will Implementers and Markets Respond to New WHO Guidelines?

Organisers: UNITAID, WHO & Pangaea

Location: Mini Room 4

The World Health Organization (WHO) will soon release 2013 HIV Treatment Guidelines. With stronger recommendations for viral load monitoring, national HIV programs will need to continue CD4 scale-up and increase access to viral load monitoring. Countries will need to develop national strategic plans that ensure strategic, equitable and cost-effective deployment of safe and effective laboratory-based and point-of-care diagnostic services across their health systems. This session will provide a high-level strategic framework on implementation of WHO guidelines for CD4 and viral load monitoring and review challenges and implications of implementing the new guidelines. This session will be of interest to donors, policy makers, civil society, and implementing organizations.

ANRS Satellite Symposium: What Can We Learn from Post-Treatment Controllers? (TUSA03)

Organisers: ANRS

Location: Mini Room 3

Long-term control of HIV replication has been observed in patients from France who initiated cART during primary infection, then stopped the treatment. The ANRS VISCONTI study of 14 post-treatment controllers (PTC) shows that these patients present low levels of HIV reservoirs, like natural HIV controllers (HIC), but have different immune-genetic characteristics. Moreover, the probability of viral control after interruption of a durable treatment initiated early in primary infection appears higher (5-15%) than the frequency of spontaneous control.

WEDNESDAY, 3 JULY

08:50 - 10:30 PLENARY SESSION (WEPL01)

Location: Session Room 1

Presentations in this session:

J.V.R. Prasada Rao, India, *Tracking the HIV and AIDS Epidemic in Asia and the Pacific*

Dennis Burton, United States, *New Developments in Protecting Antibodies*

Karine Lacombe, France, *HIV and Hepatitis C Co-Infection*

10:00 – 10.45 OFFICIAL PRESS CONFERENCE

Late Breakers Track C

Location: Media Centre, Press Conference Room

An opportunity to hear late breaker speakers from Track C

11:00 – 12:00 OFFICIAL PRESS CONFERENCE

Meet the Plenary Speakers and Closing Session speakers

Location: Media Centre, Press Conference Room

An opportunity to hear from Wednesday's plenary and closing session speakers.

11:00 – 12:30 ORAL ABSTRACT SESSION TRACK B (WEAB01)

Reach for the Top: Can We Perfect Current ART?

Location: Session Room 1

11:00 – 12:30 ORAL ABSTRACT SESSION TRACK C (WEAC01)

Three A's of Chemoprophylaxis: Acceptability, Access and Adherence

Location: Session Room 2

11:00 – 12:30 SYMPOSIA SESSION (WESY01)

Growing Up with HIV: Transitioning Adolescents to Adult Care

Location: Session Room 3

This session is directed to clinicians and health care personnel who care for children and youth with perinatal HIV infection. Youth from the developing world will reflect on their experiences growing up with HIV. Then strategies to optimize antiretroviral therapy (ART) and promote adherence as well as diagnosis and management of complications from ART will be reviewed. Finally, the session will discuss approaches to HIV cure in perinatally infected population on long-term treatment.

12:00 – 12.45 OFFICIAL PRESS CONFERENCE

Late Breakers Track D

Location: Media Centre, Press Conference Room

An opportunity to hear late breaker speakers from Track D

12.45 – 14.00 MEET THE EXPERTS SESSION (WEME01)

Meet the HIV and TB Experts

Location: Session Room 3

The HIV and TB co-epidemic has provided challenges in management at the individual as well as public health levels. In this session a panel of HIV/TB experts will discuss challenging scenarios commonly confronting clinicians and public health officials alike. The audience will have opportunities to ask questions throughout the session and to engage directly with the panel of experts.

14.30 – 16.00 ORAL ABSTRACT SESSION: TRACK B (WEAB02)

Organ Dysfunction in HIV: It's Complicated

Location: Session Room 2

14.30 – 16.00 ORAL ABSTRACT SESSION TRACK A (WEAA01)

Innate and Intrinsic Regulation of Viral Replication: Catch Me if You Can

Location: Session Room 3

14.30 – 16.00 SYMPOSIA SESSIONS

Treatment as Prevention in Asia: Progress and Challenges (WESY02)

Location: Session Room 1

HPTN 052 and multiple ecological and cohort studies have suggested that expansion of HIV treatment may be able to decrease new HIV transmissions. This session will provide an update regarding recent developments in HIV prevention efforts in southeast Asia and in specific countries and will review current progress in specific components of treatment as prevention including expanded HIV testing, diagnosis, linkage to and engagement in care, access to and uptake of treatment, initiation of ART as per local guidelines, as well as prevention for HIV-positive persons in care.

Integration and its Discontents (WESY03)

Location: Session Room 4

Although integration of HIV services with general primary and other health care is an accepted objective and aspirational goal for building on existing HIV/AIDS health platforms, few rigorous evaluations of possible pitfalls or limitations have been conducted. This session will review the successes and challenges of integrating HIV services with other health services (e.g., antenatal care, general primary care, reproductive health care, tuberculosis care) from the perspective of efficiency and effectiveness.

WEDNESDAY, 3 JULY

16:30 - 17:30 ORAL ABSTRACT SESSION (WELBA)

Late Breaker Track A

Location: Session Room 3

16:30 - 17:30 ORAL ABSTRACT SESSION (WELBB)

Late Breaker Track B

Location: Session Room 2

16:30 - 17:30 ORAL ABSTRACT SESSION (WELBC)

Late Breaker Track C

Location: Session Room 1

16:30 - 17:30 ORAL ABSTRACT SESSION (WELBD)

Late Breaker Track D

Location: Session Room 4

18:00 - 19:30 RAPPORTEUR AND CLOSING SESSION (WEPL02)

Location: Session Room 1

The rapporteur reports will summarize the major findings and issues discussed in each of the four conference tracks, and will also include a community statement.

These reports will be followed by closing remarks by the Conference International Chair and Local Co-Chair and an introduction to the IAS 2015 host city of Vancouver by IAS 2015 Local Co-Chair, Julio Montaner, Chair in AIDS Research and Head of Division of AIDS in the Faculty of Medicine at the University of British Columbia, Vancouver and Chris Beyrer, IAS 2015 International Chair, Professor of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, US